|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
<i>In vivo</i>, abemaciclib, when administered in an adjuvant setting for the second week after fractionated IR, further inhibited vasculogenesis and tumor regrowth, with sustained inhibition of RB/E2F activity, mTOR pathway, and HIF-1 expression.
|
29716919 |
2018 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
19/30 (63%) of BRCA1 tumors showed perinecrotic (hypoxia induced) and 8/30 (27%) a diffuse HIF-1alpha overexpression pattern, the latter more likely related to genetic alterations in oncogenes and tumor suppressor genes.
|
18030615 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
2-methoxyestradiol (2ME2) is a microtubule inhibitor that potently inhibits HIF1α, GBM angiogenesis and tumor growth in preclinical models.
|
24162827 |
2014 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors derived from HIF-1alpha-overexpressing cells revealed an increase in apoptosis when compared to control tumors, in spite of a marked increase in vascular density.
|
16010420 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor HIF-1alpha expression was examined in 79 patients.
|
19028277 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumour hypoxia activates hypoxia-inducible factor-1 (HIF-1) and indluences angiogenesis, cell survival and invasion.
|
20978507 |
2010 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissues from mice treated with the Pmp53 plasmid showed increased expression of p21 and decreased expression of hypoxia-inducible factor 1α proteins, with an increased apoptotic effect.
|
21444629 |
2011 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor volume, survival and expression of HIF-1 and associated molecules were evaluated in treatment versus control groups.
|
22472348 |
2012 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumor tissue was examined histologically for presence of the KRAS mutations and for expression of hypoxia-inducible factor-1 (HIF-1) and minichromosome maintenance protein 2 (mcm2).
|
24516257 |
2014 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Tumors that hemorrhaged had higher IHC staining for CD34 and CD105. mRNA expression analysis revealed tumor hemorrhage was associated with increased expression of HIF1α and MDK, and decreased expression of F3.
|
28102487 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumors with intact HIF-1α subjected to HD-SFRT immediately following hypoxia exposure were less responsive to treatment than tumors without functional HIF-1α, and tumors irradiated under air breathing conditions regardless of HIF-1α status.
|
28619042 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Tumor HIF-1α-positivity correlated to increased breast cancer mortality, and negative prognostic factors including low age at diagnosis and ER-negativity.
|
31821370 |
2019 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 controls cellular and systemic responses to oxygen availability and coordinates up-regulation of genes involved in many pathways concerned with tumour growth and metabolism including angiogenesis, glucose and energy metabolism, cellular proliferation, differentiation and viability, apoptosis, pH regulation and matrix metabolism.
|
12558074 |
2003 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1alpha was detected in tumor cell nuclei of both hemangioblastomas and CC-RCCs.
|
16024619 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1alpha contributes to tumor aggressiveness, invasiveness, and resistance to radiotherapy and chemotherapy.
|
16294030 |
2005 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha expression affects glioma tumor growth, suggesting clinical applications for malignant glioma treatment.
|
16612574 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha immunopositivity increased through the tumor development with highest expression in the late nodular stages.
|
16899596 |
2006 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha mRNA expression is differentially upregulated in esophageal squamous cell carcinoma compared to adenocarcinomas, but does not predict tumor regression or prognosis.
|
17201171 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha expression correlated well with TP53 expression levels in primary tumors, but not in recurrences.
|
17359291 |
2007 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 activates gene expression of the two genes and promotes tumor cell survival under hypoxic conditions.
|
18636206 |
2008 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1 is also linked to the regulation of tumor development and growth.
|
18949419 |
2008 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha levels were higher in human gliomas harboring an IDH1 mutation than in tumors without a mutation.
|
19359588 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1 plays a central role in malignant progression by inducing the expression of various genes, whose functions are strongly associated with malignant alteration of the entire tumor.
|
19459851 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
HIF-1alpha action may also modulate mitochondrial function and oxygen consumption by inactivating the pyruvate dehydrogenase complex in some tumor types, or by modulating cytochrome c oxidase subunit 4 expression to increase oxidative phosphorylation in other cancer cell lines.
|
19689405 |
2009 |
|
Neoplasms
|
0.100 |
AlteredExpression
|
group |
BEFREE |
HIF-1alpha expression correlated with high tumour grade (P=0.009), negative oestrogen receptor (ER) status (P=0.001) and the absence of lymph node metastasis (P=0.028).
|
19724277 |
2009 |